Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Teva to Acquire Emalex Biosciences for $700M, Adding Registration-Ready Tourette Syndrome Drug Ecopipam

Fineline Cube Apr 30, 2026
Company Deals

Eccogene Files Hong Kong IPO Prospectus with THR-β Agonist ECC4703 Leading Metabolic Disease Pipeline

Fineline Cube Apr 30, 2026
Company Deals

Hengrui Pharmaceuticals Replaces Hansoh as Exclusive Licensee for KiOmed’s Osteoarthritis Drug in Greater China

Fineline Cube Apr 30, 2026
Company Deals

Fosun Pharma and Arcera Life Sciences Forge Strategic Partnership to Bridge Chinese Biotech Innovation with Global Markets

Fineline Cube Apr 29, 2026
Company Deals

Hengrui Pharmaceuticals Partners with Sun Yat-sen University to Integrate Industry-Academia Innovation Ecosystem

Fineline Cube Apr 29, 2026
Policy / Regulatory

NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting

Fineline Cube Apr 27, 2026
Company Drug

BeOne Medicines’ Tislelizumab-Zanidatamab Combo Receives FDA Priority Review for HER2-Positive Gastric Cancer

Fineline Cube Apr 30, 2026
Company Drug

Hansoh Pharmaceutical’s B7-H3 ADC HS-20093 Receives China BTD for Advanced Prostate Cancer

Fineline Cube Apr 30, 2026
Company Policy / Regulatory

U.S. House of Representatives to Review the Biosecure Act Amid Legislative Hurdles

Fineline Cube Sep 6, 2024

The U.S. House of Representatives is slated to take up the contentious Biosecure Act the...

Company Deals

Eli Lilly Partners with Genetic Leap for RNA-Targeted AI Drug Discovery

Fineline Cube Sep 6, 2024

Eli Lilly & Co. (NYSE: LLY), a leading pharmaceutical company based in the U.S., has...

Company

Euroapi to Downsize API Production, Citing Asian Competition and Market Stagnation

Fineline Cube Sep 6, 2024

Euroapi (EPA: EAPI), a French company and a spinoff from Sanofi established in 2022, has...

Company Deals

Rigel Pharmaceuticals Strikes Deal with Kissei for Development and Commercialization of Rezlidhia in East Asia

Fineline Cube Sep 6, 2024

Rigel Pharmaceuticals Inc. (NASDAQ: RIGL), a biopharmaceutical company based in the U.S., has entered into...

Company Drug

Sinocelltech’s Herpes Zoster Vaccine SCTV04C Clears NMPA for Clinical Trial

Fineline Cube Sep 6, 2024

Sinocelltech Group Ltd (SHA: 688520), a biopharmaceutical company based in China, has received approval from...

Company Deals

Voyager Therapeutics Secures Licensing Deal with Novartis for Gene Therapy Capsid

Fineline Cube Sep 6, 2024

Voyager Therapeutics Inc. (NASDAQ: VYGR), a U.S.-based biotechnology company, has announced a licensing agreement with...

Company Medical Device

Fujirebio’s HBsAg Detection Kit Receives NMPA Approval, Enhances Early Diagnosis Capabilities

Fineline Cube Sep 6, 2024

Fujirebio Inc., a leading diagnostic company based in Japan, has received approval from China’s National...

Company Drug

Jiangsu Kanion Pharmaceutical Gets NMPA Go-Ahead for Psoriasis Drug Clinical Trial

Fineline Cube Sep 6, 2024

Jiangsu Kanion Pharmaceutical Co., Ltd (SHA: 600557), a prominent pharmaceutical company based in China, has...

Company Medical Device

Genesis MedTech Secures NMPA Approval for Innovative Surgical Energy Products

Fineline Cube Sep 6, 2024

Genesis MedTech, a leading medical device company headquartered in Singapore, has secured marketing approvals from...

Company Medical Device

True Health’s Advanced Microwave Ablation System Gains NMPA Nod for Liver Tumor Treatment

Fineline Cube Sep 6, 2024

True Health (Guangdong Hengqin) Medical Technology Co., Ltd has received marketing approval from China’s National...

Company Medical Device

Venus Medtech Initiates Global Study with Venus Vitae TAVR System Implantations

Fineline Cube Sep 6, 2024

Venus Medtech (Hangzhou) Inc., listed on the Hong Kong Stock Exchange as HKG: 2500, has...

Policy / Regulatory

China’s Hainan Free Trade Port Implements ‘Zero Tax’ on Medical Imports for Designated Entities

Fineline Cube Sep 6, 2024

In a joint effort to bolster healthcare services, China’s Ministry of Finance, National Health Commission...

Company Drug

Viatris Launches First-of-Its-Kind Nasal Spray Dymista in China for Allergic Rhinitis

Fineline Cube Sep 6, 2024

Viatris Inc. (NASDAQ: VTRS), a leading global pharmaceutical company based in the U.S., has announced...

Company Medical Device

Sansure Biotech Wins NMPA Nod for ALDH2 Gene Polymorphism Detection Kit

Fineline Cube Sep 5, 2024

Sansure Biotech Inc., (SHA: 688289), a leading molecular diagnostics company based in China, has announced...

Company Drug

Novo Nordisk Advances in China with Submission of Sogroya for Adult Growth Hormone Deficiency

Fineline Cube Sep 5, 2024

Denmark’s pharmaceutical heavyweight, Novo Nordisk (NYSE: NVO), has reached a significant milestone with the National...

Company

AstraZeneca China Restructures Biopharma Unit to Boost Chronic Disease Management

Fineline Cube Sep 5, 2024

AstraZeneca (NASDAQ: AZN)’s Chinese subsidiary has announced a strategic restructuring of its China biopharmaceutical business...

Company Drug

Kelun-Biotech’s ADC for Cancer Gets NMPA Review, Expands MSD Collaboration

Fineline Cube Sep 5, 2024

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) has achieved a regulatory milestone with its clinical...

Company Deals R&D

Eli Lilly Partners with Haya Therapeutics to Tap the Dark Genome for Obesity Treatments

Fineline Cube Sep 5, 2024

Eli Lilly & Co. (NYSE: LLY), a leading figure in the pharmaceutical industry, has embarked...

Company Drug

Roche’s Columvi for Relapsed DLBCL Gets Review Nod from China’s CDE for New Indication

Fineline Cube Sep 5, 2024

The Center for Drug Evaluation (CDE) in China has accepted for review an additional indication...

Company Drug

Jiangsu Hengrui’s Ivarmacitinib for Adult Alopecia Areata Accepted for Review by China’s CDE

Fineline Cube Sep 5, 2024

The Center for Drug Evaluation (CDE) has given the green light for the review of...

Posts pagination

1 … 295 296 297 … 660

Recent updates

  • BeOne Medicines’ Tislelizumab-Zanidatamab Combo Receives FDA Priority Review for HER2-Positive Gastric Cancer
  • Innovent Biologics Reports 50% Q1 Revenue Growth to $555M Driven by NRDL TKIs and Integrated Portfolio Strength
  • Hansoh Pharmaceutical’s B7-H3 ADC HS-20093 Receives China BTD for Advanced Prostate Cancer
  • Teva to Acquire Emalex Biosciences for $700M, Adding Registration-Ready Tourette Syndrome Drug Ecopipam
  • AbbVie Reports 12.4% Revenue Growth in Q1 2026 Driven by Immunology and Neuroscience Strength
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

BeOne Medicines’ Tislelizumab-Zanidatamab Combo Receives FDA Priority Review for HER2-Positive Gastric Cancer

Company

Innovent Biologics Reports 50% Q1 Revenue Growth to $555M Driven by NRDL TKIs and Integrated Portfolio Strength

Company Drug

Hansoh Pharmaceutical’s B7-H3 ADC HS-20093 Receives China BTD for Advanced Prostate Cancer

Company Deals

Teva to Acquire Emalex Biosciences for $700M, Adding Registration-Ready Tourette Syndrome Drug Ecopipam

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.